KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib (original) (raw)

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract, arising from interstitial cells of Cajal. They often express KIT and typically have mutations in the KIT or PDGFRA genes. This research evaluates the relationship between KIT immunohistochemistry and mutation status in GISTs, analyzing cases for treatment response to imatinib. The findings indicate that mutation status can influence therapy outcomes, leading to potential improvements in diagnostic and treatment protocols for GIST patients.